Popular Eli Lilly (LLY) weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) 澳洲幸运5官方开奖结果体彩网:approval last month.

A 澳洲幸运5官方开奖结果体彩网:Center for Medicare and Medicaid Service🌠s spokesperson told Investopedia Thursday that "current 澳洲幸运5官方开奖结果体彩网:Medicare Part D and Medica🥂id coverage rules apply" to Zဣepbound, meaning, it can be added to Part D plans and covered by Medicare. Millions of Americans are estimated to suffer from obstructive sleep apnea, a sleep disorder.

Eli Lilly and Ozempic and Wegovy-maker Novo Nordisk (NVO) are testing their weight-loss drugs' abilities to treat conditions that typically accompany obesity, such as diabetes and sleep apnea. The change was first reported Wednesday by CNBC.

"This is good news for Medicare beneficiaries living with moderate-to-severe obstructive sleep apnea (OSA) and obesity, particularly because there are no other pharmacological treatments for the underlying disease," an Eli Lilly spokesperson said in a statement to Investopedia. "We’re pleased to see Centers for Medicare & Medicaid Services affirm that their guidance from last March applies to OSA."

The drug can also be covered by state-level Medicaid programs if it is prescribed to treat sleep apnea, and if the drug maker is part of a Medicaid drug rebate program. About 780 companies participate in the rebate program, which covers drugs under Medicaid plans in exchange for the companies paying rebates that are split between states and the federal government to offset the cost of the drugs.

Zepbound was approved to treat sleep apnea 澳洲幸运5官方开奖结果体彩网:after clinical trials found that patients taking the drug 澳洲幸运5官方开奖结果体彩网:with or without traditional sleep apnea treatmen🌳ts, like a ma🅘sk, experienced a reduction in breathing interruptions during a night of sleep.

The 澳洲幸运5官方开奖结果体彩网:Biden administration in N🎀ovember proposed including the weight loss drugs in 澳洲幸运5官方开奖结果体彩网:Medicare and Medicaid plans as a prescribed treatment for obesity.

UPDATE: This story has been updated with a statement from Eli Lilly.